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SUMMARY 
Deletion or duplication of one copy of the human 16p11.2 interval is tightly associated with 
impaired brain function, including autism spectrum disorders (ASD), intellectual disability disorder 
(IDD), and other phenotypes, indicating the importance of gene dosage in this copy number variant region 
(CNV). The core of this CNV includes 25 genes, however, the number of genes that contribute to these 
phenotypes is not known. Further, genes whose functional levels change with deletion or duplication 
(termed “dosage sensors”), which may associate the CNV with pathologies, have not been identified. 
Using the zebrafish as a tool, a set of 16p11.2 homologs was identified, primarily on chromosomes 3 and 
12.  Use of eleven phenotypic assays, spanning the first five days of development, demonstrates that this 
set of genes is highly active, such that 21 out of 22 homologs tested show loss of function phenotypes. 
Most genes are required for nervous system development – impacting brain morphology, eye 
development, axonal density or organization, and motor response. In general, human genes can substitute 
for the fish homolog, demonstrating orthology, and consistent with conserved molecular pathways. In a 
screen for 16p11.2 genes whose function is sensitive to hemizygosity, the aldolase a (aldoa) and kinesin 
family member 22 (kif22) genes were identified as giving clear phenotypes when RNA levels are reduced 
by ~50%, suggesting that these genes are deletion dosage sensors. This study leads to two major findings. 
The first is that the 16p11.2 region comprises a highly active set of genes, which may present a large 
genetic target, and may explain why multiple brain function and other phenotypes are associated with this 
interval.  The second major finding is that there are (at least) two genes with deletion dosage sensor 
properties amongst the 16p11.2 set, which may link this CNV to brain disorders including ASD and IDD. 
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INTRODUCTION 
 Copy number variation (CNV), where intervals of the genome are deleted or duplicated, has been 
associated with multiple human diseases including infectious, autoimmune and neuropsychiatric disorders 
(Fanciulli et al., 2010). The 16p11.2 CNV comprises two direct repeats of 143 kbp and a central core of 
593 kbp, which includes 25 putative protein-coding genes (Ghebranious et al., 2007; Sebat et al., 2007), 
and is associated with a multitude of disorders, most commonly with speech/developmental delay (often 
characteristics of intellectual disability disorder (IDD)) (85% of deletion carriers) and autism spectrum 
disorders (ASD, 19-28% of deletion carriers) (Ciuladaite et al., 2011; The Simons Vip, 2012). In addition 
to IDD (Bijlsma et al., 2009) and ASD (Kumar et al., 2008; Marshall et al., 2008; Weiss et al., 2008), 
deletion and/or duplication of 16p11.2 are associated with seizure disorder (Ghebranious et al., 2007), 
obesity or being underweight (Jacquemont et al., 2011), macro- or microcephaly (Shinawi et al., 2010), 
schizophrenia (McCarthy et al., 2009), ADHD (Lionel et al., 2011), eye anomalies (Bardakjian et al., 
2010), heart disorders (Puvabanditsin et al., 2010), vertebral abnormalities (Shimojima et al., 2009), and 
severe combined immunodeficiency (Shiow et al., 2009). Smaller deletions within this region are also 
associated with pathologies, including ASD (Crepel et al., 2011) and abnormal sexual development 
(Tannour-Louet et al., 2010). 16p11.2 copy number changes generally occur de novo, during meiosis 
(Sebat et al., 2007), and the paucity of inherited changes indicates its importance for normal health and 
reproduction (Levy et al., 2011; Weiss et al., 2008). Consistently, mice hemizygous for the 16p11.2 
homologs exhibit a 50% rate of neonatal lethality (Horev et al., 2011). 
 A key general question is how many genes in a CNV contribute to an associated disorder. In the 
most direct case, duplication or deletion of a gene would increase or decrease cognate RNA and protein 
levels proportionally, and this change would be pivotal in development of the pathology (Nord et al., 
2011).  We term genes with such properties “dosage sensors.” In other cases, structural effects caused by 
the chromosomal rearrangement may contribute to a phenotype (Ricard et al., 2010). For the 16p11.2 
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region, a mouse model in the syntenic region shows that levels of brain expression in 79% of genes were 
affected by deletion or duplication, as predicted by gene dosage (Horev et al., 2011). Further supporting 
the notion of dosage sensitivity, in human patients, 16p11.2 duplication or deletion is sometimes 
correlated with reciprocal phenotypes, such that obesity and macrocephaly are associated with 16p11.2 
deficiency, being underweight and microcephaly with duplication (Jacquemont et al., 2011; Shinawi et al., 
2010). Similarly, opposite phenotypes exist in the hemizygous 16p11.2 region mice compared to mice 
containing the duplication, including brain volume and certain behaviors (Horev et al., 2011).   
 In this study, we use the zebrafish to analyze activity of 16p11.2 CNV genes, and to identify gene 
dosage sensors within this region. Although many abnormalities are linked to 16p11.2 CNVs, we are 
interested in the high prevalence of associated brain disorders, with particular interest in the CNV’s 
connection to ASD. Specifically, the 16p11.2 CNV is by far the most prevalent CNV to be associated 
with ASD (Sanders et al., 2011), contributing to ~1% of ASD cases. Zebrafish do not have the same 
behavioral repertoire as humans, and therefore have limitations in comparable assays for behaviors 
associated with human disorders.  However, the zebrafish genome is similar to that of the human, and 
molecular pathways engaged by homologous mammalian and fish genes are conserved. We therefore 
termed the zebrafish a “tool”, rather than a phenotypic model, for analysis of brain disorders (Sive, 2011). 
The zebrafish allows rapid functional analysis of many genes, at a rate unprecedented in mouse, due to the 
ability to obtain many embryos and to inhibit gene function in the whole embryo by injection of antisense 
oligonucleotides. There are indications that many functional brain disorders, including ASD and IDD, are 
developmental in nature, since they present soon after birth (Konopka et al., 2012; Ploeger et al., 2010). 
However, maintenance of brain structure, or faulty brain function after birth may play key roles in 
etiology of these disorders (Okado et al., 2001; Trembath, 1994). The most accessible time window for 
analysis in the zebrafish is the first five days of development, which covers the equivalent of several 
weeks in mice and a couple of years in humans, potentially addressing both developmental and later gene 
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function. Thus, results from zebrafish assays can provide useful data suggesting more targeted 
mammalian studies. 
We show here that most individual zebrafish 16p11.2 homologs are required for normal brain and 
body development, and that their function is conserved with the human gene. We also show that zebrafish 
16p11.2 homologs include at least two genes with deletion dosage sensor properties, potentially linking 
hemizygosity of the interval with human phenotypic presentations such as ASD and IDD.   
 
RESULTS 
 
Conservation and expression of zebrafish 16p11.2 homologs   
In order to use the zebrafish as an effective tool for functional analysis of the 16p11.2 CNV, we 
used the strategy shown in Fig. 1A. The 16p11.2 core spans 593 kbp and includes twenty-five protein-
coding genes.  Twenty-one of these genes in the human interval were identified in the zebrafish genome 
(Fig. 1B).  Of the remaining genes, SPN, TMEM, and C16ORF54 are limited to mammals.  SPN has a 
regulatory role in adaptive immunity (Kyoizumi et al., 2004), whereas TMEM and C16ORF54 are of 
unknown function and all three are of unknown importance in neurodevelopment. Finally, QPRT has a 
teleost homolog in Fugu (52% identity to the human protein) and Medaka (54% identity to the human 
protein), suggesting that a zebrafish homolog exists, but is not yet annotated in the genome.  
Zebrafish homologs are clustered on either chromosome 3 or 12, previously identified as the 
genomic counterparts of human chromosome 16 (Taylor et al., 2003), with the exception of ino80e, which 
is located on chromosome 16 (Table S1). These regions are not syntenic with human chromosome 16, 
since gene order is not conserved. Two sets of syntenic genes were found on chromosome 3; one region 
comprises kctd13, sez6l2 and asphd1, where the order is not conserved with human; and mapk3, gdpd3, 
and ypel3, where the order is conserved. Interestingly, the first set of syntenic genes (kctd13, sez6l2, and 
asphd1) is found in a microdeletion associated with ASD (Crepel et al., 2011).  
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Five homologs were present in two copies (aldoa, fam57b, gdpd3, ppp4c and taok2) reflecting the 
partial duplication of the teleost genome (Postlethwait et al., 2000). Genes in each pair had similar but not 
identical sequences (Table S1), with one found on zebrafish chromosome 12 and the other on 
chromosome 3. Such duplication may result in split or divergent function of the gene (Yamamoto and 
Vernier, 2011).  
In order to determine when zebrafish 16p11.2 homologs are expressed, temporal expression was 
analyzed by RT-PCR (see Methods, Fig. S1A, Table S2). Most genes are expressed maternally and 
zygotically, at least until 48 hours post fertilization (hpf). asphd1, doc2a, prrt2, and sez6l2 are expressed 
only zygotically. Whole mount in situ hybridization (Fig. S1B) showed that all genes, except tbx24, are 
expressed in the brain at 24 hpf (Thisse, 2005). 
These data indicate that the zebrafish genome includes homologs of 84% of the human 16p11.2 
core genes, arranged primarily on two homologous chromosomes. Homologs are all expressed during the 
first 48 hours of development, as the brain and other organs are forming, with almost all genes showing 
some expression in the brain. Expression data, chromosomal arrangement of the genes, and their sequence 
conservation with human, indicate that this gene set is appropriate for further analysis.  
 
Changes in brain and body morphology accompany loss of function in 16p11.2 homologs   
In order to determine which zebrafish 16p11.2 homologs were active as the brain formed and 
began to function, we screened these for activity during brain development, from 24 hpf through 5 days 
post-fertilization (dpf), the human developmental equivalent of five weeks of gestation to toddlerhood. 
Loss of function (LOF) was performed by injection of antisense morpholino oligonucleotides (MOs) into 
one to two cell embryos. Where possible, MOs binding to an exon/intron boundary were utilized (Table 1, 
Table S2), to target zygotic RNA.  Where a splice site MO did not give a phenotype, a MO directed 
against the translational start site was tested to determine whether maternal RNA could have prevented 
observing a phenotype with a splice site MO (Table 1, Table S2) and the resulting effects on predicted 
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protein are included in Table 2. Where two copies of a gene had been characterized, in some cases, only 
one was highly expressed in the brain and this was assayed for a LOF phenotype. In the case of taok2, 
both genes showed strong brain expression (Fig. S1), and both were assayed. Thus, twenty-two genes 
were tested for LOF phenotypes. 
MO methodology is rapid and allows functional analysis of many genes, however, specificity of 
phenotypes associated with MOs was carefully tested, as off target effects can sometimes be observed 
(Bedell et al., 2011; Eisen and Smith, 2008). The criteria employed to test specificity were as follows, and 
are described more fully in Methods, with results documented in Table 1, and quantified in Table 2 and 
Table 3. First, for MOs targeting a splice donor or acceptor site, a change in RNA splicing and coding 
capacity should be observed. Second, the corresponding amount of normal RNA should be reduced, and a 
phenotype should correlate with RNA reduction. Use of splice site MOs allows these assays to be 
performed quantitatively, as normal RNA can be distinguished from abnormally spliced RNA. Third, a 
key assay for specificity is the ability of RNA derived from the corresponding human or zebrafish cDNA 
to prevent the LOF phenotype, when co-injected with the appropriate MO. Such “rescue” RNAs do not 
contain the MO binding site, due to species differences or because the MO binding site lies across a splice 
junction. Fourth, off-target effects of MOs may cause cell death, which can effectively be suppressed by 
injection of a p53 MO (Robu et al., 2007). Where severe phenotypes were observed, the effect of p53 
suppression is tested and if a resulting phenotype was milder, it is the one scored. Finally, comparison of a 
phenotype obtained with MOs is compared to mutants (or shRNAs) to test similarity of phenotypes. Since 
mutants are available for a very limited number of genes, we focused on MO-mediated LOF, which is the 
most feasible way to assay the activity of the large 16p11.2 gene set.  
LOF embryos were first examined at 24 hpf for brain morphology, after injection of the brain 
ventricles with Texas Red dextran (Gutzman and Sive, 2009), and scored for brain shape, presence of 
forebrain, midbrain and hindbrain hingepoints, brain ventricle size, forebrain truncation, and eye 
morphology. Tail and body phenotypes were assayed as additional indicators. For each gene, each 
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phenotype reported was observed in at least two independent experiments, and observed for at least 70% 
of embryos examined, using MO amounts that had been titrated (Table 2) and gave a clear phenotype 
(with quantification presented in Table S3).  
Strikingly, LOF for almost all genes (twenty out of twenty-two assayed), with the exception of 
prrt2 and tbx24, led to changes in brain or eye morphology (Fig. 2A, Fig. 3, Table S3). These phenotypes 
are characterized further in Fig. 2B,C. tbx24 LOF was associated only with a tail phenotype, consistent 
with a lack of brain expression of this gene, and with the mutant phenotype (Fig. S2), (Thisse, 2005). 
Thus, a total of twenty-one out of twenty-two genes examined gave a LOF phenotype. In addition to their 
brain phenotypes, LOF in all but six genes (cdipt, doc2a, fam57ba, kctd13, prrt2, and taok2a) led to tail 
or body defects, including failure of the yolk cell to extend, a short, bent tail and abnormally shaped 
muscle segments (Fig. 2A, Fig. 3, Table S3). Several genes gave very strong phenotypes, suggesting early 
embryonic defects.  In particular, coro1a, ino80e, mapk3 and mvp “morphants” (defined as LOF embryos 
caused by MO injection) showed abnormal body length and defective neural tubes. mapk3 LOF embryos 
showed a defective forebrain, eyes, and a short body, consistent with a recent study (Krens et al., 2008). 
coro1a, maz and fam57ba morphants have small eye cups with protruding lenses (Schmitt and Dowling, 
1994). LOF in asphd1 and sez6l2 gave weak phenotypes, while no phenotype was observed after prrt2 
LOF. Since prrt2 is not highly expressed until 48 hpf, gene function may be required later (Fig. S1A).  
Two clear groups of brain morphology phenotypes were apparent (Fig. 2B,C).  LOF in the first 
group of genes was associated with reduced brain ventricle size, and the midbrain-hindbrain boundary 
(MHB) was less sharply defined than in controls.  This group includes c16orf53, cdipt, doc2a, hirip3, 
kctd13, and taok2b (Fig. 2B), which have not previously been shown to regulate brain morphology, 
although cdipt is required later in lens and photoreceptor development in zebrafish (Murphy et al., 2011), 
and Doc2a is a modulator of synaptic transmission in mice (Yao et al., 2011). These phenotypes may 
result from changes in neuroepithelial specification, morphogenesis, or reduction in cerebrospinal fluid 
volume (Gato and Desmond, 2009; Lowery and Sive, 2009). 
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
Ac
ce
pt
ed
 m
an
us
cr
ip
t
 9 
A second group of genes leading to defective brain morphology after LOF showed a straight 
midbrain (Fig. 2C), where the midbrain hingepoint was essentially absent. This phenotype was seen in 
aldoaa, fam57ba, gdpd3, maz, ppp4ca, and ypel3 morphants, a group of genes with previously undefined 
contributions to brain development.  gdpd3, ppp4ca and ypel3 LOF embryos showed a wider opening at 
the MHB, relative to the narrowing seen in control embryos.  A subset of embryos from both groups 
showed a narrowed forebrain, such as those seen in aldoaa, fam57ba, and maz LOF embryos, while the 
area rostral of the eyes was reduced after fam57ba, gdpd3, hirip3, and maz LOF. Expression of pax2a at 
the MHB was normal, indicating correct specification of this region, and suggesting that later steps 
resulted in the phenotypes observed (not shown). Although the groupings shown in Figs. 2B,C suggest 
similar contribution to brain development by all genes in the group, close comparison reveals distinct 
phenotypes; for example, aldoaa and ypel3 morphants have similar midbrain phenotypes, but MHB and 
hindbrain phenotypes are unique. 
For all but three genes, co-injection of RNA derived from the human cDNA together with the MO 
generally restored the phenotype, indicating fish/human orthology, and confirming the specificity of the 
phenotype (Tables 1 and 3, Fig. 4). For kctd13 and maz, the zebrafish, but not the human gene, rescued 
the LOF phenotype. mvp LOF gave a similar phenotype with three tested MOs, but was not reproducibly 
rescued by fish or human cDNAs, perhaps reflecting a stoichiometric requirement for other components 
with which mvp complexes (Berger et al., 2009). Embryos were scored as rescued if morphological and 
behavioral phenotypes were ameliorated in ~ 50% or more embryos (see Fig. 4 and Table 3).  For strong 
phenotypes, such as gdpd3 and mapk3 LOF, rescues vastly improved brain and body morphology, but did 
not fully restore a wildtype phenotype. Assays for rescue included observation of the shape of the brain, 
ventricle size, and eye morphology, movement and axon tracts. 
In summary, twenty-one out of twenty-two zebrafish 16p11.2 homologs tested are required for 
early brain and/or body development, with the majority showing conserved function with the cognate 
human gene. The data therefore show that this set of genes is highly active during early development. 
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Movement deficiency is associated with loss of function in some 16p11.2 homologs 
We next assessed motor function as a read-out of neural circuitry, by assaying two early 
behaviors: spontaneous movement at 24 hpf and the touch response at 48 hpf as described in Methods 
(Liu et al., 2012; Naganawa and Hirata, 2011). LOF in seven genes (coro1a, fam57ba, gdpd3, hirip3, 
kif22, maz and ppp4ca) was associated with spontaneous movement defects. LOF in fourteen genes led to 
a defect in touch response in at least 70% of embryos for each gene examined (Fig. 3, Table S3). In the 
most severe cases, aldoaa and fam57ba, LOF embryos exhibited no response to touch, and these severe 
phenotypes were rescued by co-injection with human RNA. A sluggish response to touch, rather than the 
normal rapid C-bend and brief swim, was observed in coro1a, gdpd3, hirip3, kctd13, kif22, maz, and 
ppp4ca morphants. The response to touch is improved by the addition of rescue RNA. Abnormal, U-
shaped muscle segments and/or a short, bent tail were seen in the spontaneous movement- and touch 
response-defective aldoaa, coro1a, fam57ba, gdpd3, kif22 and hirip3 LOF embryos, perhaps explaining 
the movement defects (Fig. 2A, Fig. 3, Table S3). These data indicate that multiple 16p11.2 homologs 
were required for normal motor activity, as reflected by spontaneous movement or touch-responsiveness.  
 
A subset of genes is required for normal axon tract development 
Motor deficiencies observed in LOF embryos led us to ask whether axon tract formation is 
affected. Both forebrain and hindbrain axon tracts were analyzed by immunostaining for acetylated α-
tubulin and confocal imaging at 36 hpf, when initial scaffolding has formed (Fig. 5). Embryos with 
deficient axon tracts were seen in more than 80% of embryos, after LOF in each of six genes: coro1a, 
fam57ba, kctd13, kif22, mapk3 and ppp4ca (Fig. 5, and quantification in legend). LOF in all of these 
genes led to reduced and disorganized tracts, however the kctd13 LOF forebrain tract phenotype was 
mild, and kif22 LOF hindbrain tracts appeared normal. For each gene, normal phenotypes were observed 
in at least 75% of embryos examined after co-injection of cognate human mRNA (or fish mRNA for 
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
Ac
ce
pt
ed
 m
an
us
cr
ip
t
 11 
kctd13) with the antisense MO, further supporting conservation of function and specificity of the axon 
tract phenotypes caused by MO injection (Fig. 5).  
In addition to brain axon tract deficiencies, we demonstrated that pigmentation, indicative of 
neural crest lineages that include peripheral nerves (Schilling and Kimmel, 1994), was abnormal after 
LOF in a subset of homologs (Fig. S3). Some of these also presented with axon tract abnormalities 
(coro1a, fam57ba, mapk3 and ppp4ca). Interestingly, for six genes (coro1a, fam57ba, kctd13, kif22, 
mapk3 and ppp4ca) where LOF gave a movement or touch response phenotype, an axon tract and/or 
pigmentation defect was also apparent (Fig. 3), perhaps connecting these phenotypes to the abnormal 
behavior (An et al., 2002; Haffter et al., 1996; Marmigere and Ernfors, 2007). For four genes (maz, mvp, 
tbx24 and ypel3), a touch response phenotype seen after LOF was not accompanied by axon tract or 
pigmentation aberrations, implicating abnormal muscle activity in the phenotype. However, while axon 
tracts may appear normal, synaptic transmission may be defective. These data show that multiple 16p11.2 
homologs are necessary for normal axon tract development – suggesting deficits in formation of neuronal 
precursors, guidance, or fasciculation – and that axonal deficiencies may be linked to motor phenotypes. 
 
Identification of aldoaa and kif22 as deletion dosage sensor genes  
 A major goal of this study was to determine whether any 16p11.2 homologs had the properties 
of deletion dosage sensors, which may be associated with IDD, ASD and other phenotypes.  We define a 
deletion dosage sensor as a gene that gives a phenotype after a 50% decrease in expression, in accord with 
the simplest outcome of loss of one gene copy. Our initial assays for function of 16p11.2 homologs (Figs. 
2,3) used MO concentrations that led to a clear phenotype, however, the associated decreases in RNA 
expression were not determined. In order to identify whether any of these genes are deletion dosage 
sensors, we assessed the lowest dose of MO that led to a phenotype, and quantified the amount of normal 
RNA remaining at this concentration using qPCR (Fig. 6). This approach was used for the fourteen genes 
whose function was inhibited by splice site MOs, where abnormal splicing had been detected and the 
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normal and abnormal transcript could be distinguished, using appropriate primers (Fig. 6B, Table 1, Table 
S2).  Due to standard error intrinsic to the qPCR process, genes were designated putative deletion dosage 
sensors if a phenotype was observed when between 40% and 60% normal RNA remained, although a 
deletion dosage sensor could also be sensitive to smaller decreases in expression (>60% of RNA 
remaining). 
Most genes tested showed a LOF phenotype only when 25% or less normally spliced RNA 
remained (Fig. 6C). However, two genes, aldoaa and kif22, were reproducibly associated with a 
phenotype when approximately 45% RNA remained for aldoaa and 55% RNA remained for kif22 (Fig. 
6C), suggesting that these genes are deletion dosage sensors. Although RNA levels were initially 
quantified at 24 hpf, approximately 50% of normal levels were present also at 18 and 36 hpf (Fig. 6D) 
(for aldoaa and kif22 respectively, 64% and 52% of normal levels were present at 18 hpf, and 67% and 
41% of normal levels were present at 36 hpf). Importantly, the decrease in RNA expression was mirrored 
at the protein level, where Western blot analysis showed a 56% and 65% loss of Aldoaa and Kif22 protein 
expression, respectively, after MO injection (Fig. 6E).  
The sensitivity of embryos to aldoaa and kif22 to 50% LOF led us to examine the phenotypes 
obtained in more detail. Thus, abnormal muscle segment formation (Fig. 2) was further characterized after 
phalloidin staining, which showed U-shaped muscle segments, as well as muscle fibers that were wavy 
and poorly aligned (Fig. 6F). Since the brains in both aldoaa and kif22 LOF embryos appeared narrow 
(Fig. 2A), we asked whether formation of neural progenitors was affected at 48 hpf, using a transgenic 
line with GFP driven by the promoter of NeuroD, a pan neuronal transcription factor (Obholzer et al., 
2008; Ulitsky et al., 2011). After LOF in both aldoaa and kif22, NeuroD promoter-driven expression of 
GFP was decreased in the eyes and optic tectum, whereas expression in the cranial neurons and pancreas 
appeared unaffected (Fig. 6G).  
These data indicate that most zebrafish homologs in the 16p11.2 cohort do not have the 
characteristics of deletion dosage sensors. However, the aldolase a (aldoaa) and kinesin family member 
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22 (kif22) genes each show a robust phenotype at 50% LOF, which may indicate the effects of genetic 
hemizygosity at these loci, and designate these genes as putative deletion dosage sensors.   
 
Tissue-specific shRNA expression indicates nervous system function for aldoaa and kif22 
 In order to address whether the effects of aldoaa and kif22 LOF were due directly to changes in 
expression within the brain, or secondarily, due to effects on other tissues, shRNAs targeting these genes 
were expressed in the zebrafish brain. We used the central nervous system-specific miR124 promoter (De 
Rienzo et al., 2011; Shkumatava et al., 2009), and expressed shRNAs from the miR30 backbone (see 
Methods, (Dong et al., 2009), (De Rienzo et al., in preparation), (Fig. 7A). By testing four hairpins against 
either aldoaa or kif22, a targeting construct was identified for each gene. These constructs reduced normal 
RNA levels to 46% for aldoaa and 42% for kif22 when normalized to GFP in the whole embryo 
(reflecting total number of cells expressing the shRNA) or 64% for aldoaa and 57% for kif22 when 
normalized to β-actin in microdissected brain (reflecting total brain RNA) (Fig. 7B, 7D). For aldoaa, a 
phenotype very similar to that of the antisense MO was observed, such that touch response was highly 
defective (Fig. 7B), and the forebrain was narrow (Fig. 7C). However, the tail and muscle segment 
phenotype was not observed, in accord with nervous system-specific expression of this shRNA. The kif22 
RNAi phenotype was very similar to that seen with the antisense MO, including abnormal brain 
morphology and a bent tail (Fig. 7E). The persistent bent tail phenotype, even after nervous system-
specific expression of the kif22 shRNA, likely reflects defective convergence and extension that can be 
modulated by kif22 activity in the spinal cord (De Rienzo et al., 2011). 
These shRNA data further confirm specificity of the aldoaa and kif22 phenotypes observed using 
MOs. Similar confirmation of phenotypes obtained from MO injection or genetic mutants was seen for 
the cdipt and tbx24 genes (Fig. S2). In sum, the data demonstrate that the phenotypes observed after 
aldoaa and kif22 function are consistently seen after 50% LOF, and are due to activity of these genes in 
the brain. 
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DISCUSSION 
This study has uncovered two novel and fundamental aspects of genes within the 16p11.2 CNV. 
The first major finding is that the 16p11.2 set of genes is highly active and necessary for early 
development, indicating that the set presents a large genetic target, which may explain the penetrant 
association of 16p11.2 with multiple brain disorders and other phenotypes. The second major finding is 
that, amongst the 16p11.2 set, there are (at least) two single genes with deletion dosage sensor properties, 
which may link this CNV to ASD, IDD and other disorders.  
The finding that the majority of 16p11.2 homologs is required for normal embryonic nervous 
system and body development is consistent with the early onset of some of these disorders, which may 
suggest that key genes underlying the disorder have developmental roles. Alternately, key disorder genes 
may govern maintenance of aspects of the brain, or lead to a postnatal change in brain function. The 
finding that LOF for a majority of these genes results in persistent phenotypes through 5 dpf may imply 
that these are important for maintenance and continued function, however, we did not distinguish whether 
different mechanisms underlie early and later phenotypes. We further note that LOF phenotypes observed 
after extensive RNA knockdown will generally be more severe than those seen in hemizygous mutant fish 
or human patients. Thus, developmental phenotypes may be present after extensive knockdown, whereas 
after partial LOF, later brain function may be altered, with no apparent change to development. By 
comparison with zebrafish genetic screens, where approximately 10% of genes give an embryonic 
phenotype after mutation (Jiang et al., 1996; Schier et al., 1996), 95% of the genes tested here gave a LOF 
phenotype, almost all including the brain, suggesting that the multitude of phenotypes associated with 
16p11.2 CNV reflects activity of many genes. While the MOs used for LOF assays may sensitize the 
embryo due to their unusual nucleic acid backbone, phenotypes we observed were specific, and where 
tested, similar to that of genetic mutants (as seen in other studies, for example, De Rienzo et al., 2011). 
Accordingly, the LOF phenotypes for each gene we examined formed a unique phenotypic signature, 
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where in some cases abnormalities were seen across the entire spectrum of assays, for example, coro1a 
and fam57ba, while for other genes, only a subset of phenotypes was observed.  
Overall, it is not clear whether the mammalian set of 16p11.2 genes is as active as the fish gene 
set; however, for 16p11.2 homolog activity that has been reported, mouse and fish LOF phenotypes are 
often similar. Mouse null knockouts have been reported for only eight 16p11.2 homologs (Coro1a, 
Doc2a, Kif22, Mapk3, Mvp, Ppp4c, Sez6l2, Tbx6,) (Chapman and Papaioannou, 1998; Foger et al., 2011; 
Miyazaki et al., 2006; Mossink et al., 2002; Ohsugi et al., 2008; Pages et al., 1999; Sakaguchi et al., 1999; 
Shui et al., 2007), with one conditional knock out (Prrt2) (Skarnes et al., 2011). All of the homozygous 
knockouts are associated with phenotypes, except for Mvp (Mossink et al., 2002) and Sez6l2, which has 
other copies that are predicted to compensate (Miyazaki et al., 2006). Both Ppp4c and Tbx6 homozygous 
knockout mice are embryonic lethal; Ppp4c heterozygotes showed growth retardation with decreased 
survival, while Tbx6 heterozygotes were viable and displayed no obvious phenotypes (Chapman and 
Papaioannou, 1998; Shui et al., 2007). In contrast, tbx24 mutant zebrafish are viable (Nikaido et al., 
2002), while our ppp4ca knockdown fish still had an abnormal phenotype at 5 dpf, implying they will not 
survive. Coro1a mutant mice have lower T cell counts due to defective migration (Foger et al., 2006) and 
increased apoptosis (Mueller et al., 2011), while Mapk3 mutant mice have reduced numbers of 
thymocytes (Pages et al., 1999). We did not evaluate zebrafish immune response, however, coro1a LOF 
zebrafish showed highly abnormal axon tracts, consistent with a migration defect. Doc2a knockout mice 
exhibit defects in excitatory synaptic transmission and long-term potentiation (Sakaguchi et al., 1999), 
while knockdown of doc2a in zebrafish resulted in defective brain morphology, but apparently normal 
motor responses and axon tracts. Because the mice were studied at later stages, similar phenotypes may 
develop in older fish. Mapk3 mutant mice, in combination with Mapk1 deficiency, exhibit defective 
neurogenesis (Satoh et al., 2011), and similarly, we observed defective axon tracts in mapk3 LOF 
zebrafish. Given the broad set of phenotypes we observed, it seems likely that the extensive postnatal 
lethality of 16p11.2-region deletion mice is a result of the compound hemizygosity of multiple genes.  
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Together, the data implicate activity of many 16p11.2 genes in development and/or function of the brain 
and body. 
The second major finding from this zebrafish study, definition of the first dosage sensor genes in 
the 16p11.2 CNV, is groundbreaking because dosage sensor genes have been identified in only a handful 
of CNVs where they are pivotal for association with mental health disorders. These include SHANK3 in 
22q13 (Durand et al., 2007), RPA1 in 17q13.3 (Outwin et al., 2011), VIPR2 in 7q36.3 (Vacic et al., 2011), 
and MBD5 in 2q23.1 (Talkowski et al., 2011). We identified two genes in the 16p11.2 CNV, aldoaa and 
kif22, where a phenotype is observed after reducing their expression level by ~50% in fish, thus showing 
characteristics of deletion dosage sensors.   
ALDOA is a glycolytic enzyme that catalyzes the conversion of fructose-1,6-bisphosphate to 
glyceraldehyde-3-phosphate and dihydroxyacetone phosphate. Several other functions and roles have 
been ascribed to ALDOA, including inhibiting phospholipase D2, binding to the cytoskeleton, and 
RNAase activity (Canete-Soler et al., 2005; Kim et al., 2002; Kusakabe et al., 1997). No homozygous null 
mutations have been identified in humans, indicating that ALDOA is essential (Esposito et al., 2004). Six 
cases of hemolytic anemia and myopathy have been associated with point mutations and reduced ALDOA 
activity (Beutler et al., 1973; Esposito et al., 2004; Kishi et al., 1987; Kreuder et al., 1996; Miwa et al., 
1981; Yao et al., 2004). One case presented with mental retardation (Beutler et al., 1973), another with 
microcephaly and language delay (Kreuder et al., 1996). Further connecting this gene with mental health 
disorders, expression of ALDOA is upregulated in the cortex of patients with schizophrenia and 
depression (Beasley et al., 2006). The mitochondrial citric acid cycle, into which glycolytic end products 
feed, has been shown to be dysregulated in children with autism (Giulivi et al., 2010), pointing to 
glycolysis and energy production as possible ALDOA targets. ALDOA was identified by a protein 
interactome study as a binding partner for the ASD-linked gene SHANK3 (Sakai et al., 2011) as well as 
in a study implicating postsynaptic signaling complexes in ASD (Kirov et al., 2012). The association of 
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partial LOF in ALDOA with patient phenotypes, as well as these other considerations, suggest that 
ALDOA is a player in 16p11.2 pathologies. 
KIF22 is a microtubule and DNA binding molecular motor, important for chromosome alignment 
(Santamaria et al., 2008) and compaction during anaphase (Ohsugi et al., 2008). Patients with a point 
mutation in the motor domain of KIF22 suffer from the autosomal-dominant skeletal disorder, 
spondyloepimethaphyseal dysplasia with joint laxity (Boyden et al., 2011; Min et al., 2011). No 
phenotype has been reported in Kif22+/- mice; however, ~50% of Kif22-/- mouse embryos do not survive 
past the morula stage (Ohsugi et al., 2008). KIF22 has not previously been implicated in brain function 
disorders, but our data suggests that this gene is required for formation of neural progenitors. Since 
mammalian heterozygotes in Kif22 have not been associated with phenotypes, Kif22 expression levels 
may be regulated after loss of one gene copy, or there may be greater redundancy amongst mammalian 
Kinesins than amongst zebrafish genes. For both kif22 and aldoaa, the stronger phenotypes seen after 
partial LOF in zebrafish relative to human suggest that an additional gene(s) must synergize with ALDOA 
or KIF22 to convey ASD, IDD or other phenotypic risk in humans.   
We suggested that the zebrafish could be a useful tool to address function of 16p11.2 homologs, 
without a need to assay for behaviors restricted to humans (Sive, 2011), specifically due to use of the 
same genetic pathways in mammals and fish. Consistently, almost all zebrafish LOF phenotypes could be 
prevented by expression of the homologous human gene, supporting gene orthology and shared gene 
function at the molecular or cellular level. With reference to our specific interest in ASD, we note that 
several zebrafish phenotypes may be similar to those seen in ASD (but also in IDD) patients, including 
abnormal brain size and shape, axon tracts and motor readouts, and specification of retinal and tectal 
neural progenitors (Almgren et al., 2008; Amaral et al., 2008; Courchesne et al., 2007; Hashimoto et al., 
1991; Marin-Padilla, 1975; Matson et al., 2011; Ritvo et al., 1986) as well as musculoskeletal defects seen 
in some ASD (but also in IDD) patients (Calhoun et al., 2011; Chen, 1982; Oslejskova et al., 2007; 
Shimojima et al., 2009).    
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This work identifies the 16p11.2 CNV as an active genomic region, and delineates two putative 
deletion dosage sensor genes in the region, with predictable connection to functional brain syndromes 
associated with the CNV. These genes, in combination with additional 16p11.2 or other genes, may be 
haploinsufficient for normal brain function. Other dosage sensors in this interval may exist, perhaps as 
pairs of synergistically functioning genes. Future assays in the zebrafish will augment antisense MO 
approaches with RNAi and genetic mutants, will determine whether duplication and deletion sensor genes 
are the same, and screen for synergistic deletion and duplication dosage sensor genes in the 16p11.2 gene 
set. These unbiased screening approaches are a powerful step in translational research focusing on CNVs 
associated with disorders arising from abnormal brain development and function.  
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METHODS 
Identification of zebrafish 16p11.2 homologs 
Zebrafish homologs of human16p11.2 genes were identified using UniGene, Ensembl, and UCSC 
Genome browsers with alignment and family tree comparisons. 
 
Fish lines and maintenance 
 Embryos were obtained from natural spawnings. Developmental stages are reported as hours post-
fertilization (hpf) at 28°C. The NeuroD:GFP line, was previously described (Obholzer et al., 2008; 
Ulitsky et al., 2011). Additional mutant lines were obtained from ZIRC. The tbx24 te314a/+ line (Nikaido et 
al., 2002; van Eeden et al., 1996) was incrossed, and homozygotes identified phenotypically at 24 hpf.  
The cdipt hi559Tg/+ incrossed line (Amsterdam et al., 2004) was genotyped using the following primers:  
hi559_F1: 5’-CTAGCTTGCCAAACCTACAGG-3’ 
hi559_F2: 5’-ACGCGCCACGCTCATCTACAGTC-3’ 
hi559_R1: 5’-TGGTTGTAACGTGTAATACTACGC-3’  
A 324 bp PCR product was observed in mutants using F1 and R1, but not wildtype embryos. Wildtype 
embryos show a 524 bp PCR product using F2 and R1 primers.  
 
cDNA constructs 
 Human or zebrafish cDNAs used for rescue experiments were cloned into pCS2+ (Table S4). 
Zebrafish cDNAs used for in situ hybridization are also included in Table S4. All human and some 
zebrafish clones were obtained from Open Biosystems. asphd1, c16orf53, doc2a, maz, sez6l2, taok2a, and 
taok2b were cloned by PCR from 24 hpf zebrafish cDNA, using primers listed in Table S2. We thank Dr. 
Jeremy Green (Kings College, London) for membrane-targeted CAAX-eGFP. 
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Antisense morpholino-modified oligonucleotide design and use 
Antisense morpholino-modified oligonucleotides (MOs) were designed by Gene Tools, LLC, to a 
splice donor or acceptor site, as close to the 5’ end of the predicted primary RNA as possible. Where a 
splice site MO gave no phenotype, a translational start site MO was designed. The designed MO 
sequences are shown in Table S2.  In all cases the top MO listed (in Tables 1 and S2) for a gene was used 
in phenotypic assays described elsewhere unless otherwise noted. For all experiments, a control MO was 
injected at the same or greater mass amount.  
One nL was injected into a single cell of a 1-2 cell embryo, using a range of concentrations to 
determine the lowest concentration at which a phenotype was observed. No more than 7.5 ng of a MO 
was injected. Unless otherwise stated, the “control” condition refers to control MO-injected embryos. 
The control MO sequence is 
5’-CCTCTTACCTCAGTTACAATTTATA-3’ 
 
Criteria and methodology to assess MO specificity 
Specificity of MO-induced LOF phenotypes was determined by the following criteria, as are the 
standard for the field (Bedell et al., 2011; Eisen and Smith, 2008). First, since initial MOs were designed 
to target splice junctions (described above), it is predicted that a change in RNA splicing would be 
observed by RT-PCR. These MOs would target zygotically expressed RNAs. Primers to detect 
knockdown are included in Table S2, and RT-PCR methods are discussed below. Where a change in 
splicing was not detected, an additional splice site MO was designed. For genes where splice site MOs 
changed splicing, but did not result in an observable phenotype, a translation blocking MO was designed 
to target maternal transcripts, as well as zygotic. It is further predicted that protein-coding capacity would 
be altered. This was determined by gel purification of the RT-PCR products after control or test gene MO 
injection, and sequencing the PCR product. Protein coding capacity was determined by using Sequencher 
and MacVector software. In the cases of putative deletion dosage sensor genes, change in expression 
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resulting from MO injection was monitored at the protein level by Western blot analysis (described 
below).   
Second, for phenotypes observed after injection of splice blocking MOs, it is predicted that normal 
RNA levels will decrease, and this was monitored by qPCR, as discussed in the specific Methods section. 
Correlation between phenotype and MO mass is also predicted, and was assayed in MO titration 
experiments (Fig. 6 and methods below).   
Third, MO specificity predicts that the LOF phenotype will be prevented (“rescued”) after co-
injection of the MO with cognate human or zebrafish mRNA that lacks the MO binding site, but preserves 
protein coding capacity. The appropriate mass of RNA used in rescue experiments was based on both 
rescue of the LOF phenotype as well as the lack of an overexpression phenotype when the same RNA 
mass was co-injected with the control MO. Mass of RNA injected in rescue assays, and the success of 
rescue is listed in Table 3. GenBank Accession numbers and cDNA constructs used to synthesize RNA 
are shown in Table S4. RNA synthesis is discussed below. The rescue titration experiments had a 
minimum of 4 conditions; control MO plus mGFP to serve as a balancer RNA, LOF MO plus mGFP 
RNA, control MO plus the human/fish RNA, and LOF MO plus the fish RNA.  
Fourth, where necrosis, or a severe phenotype was observed, the p53 MO was co-injected, to 
suppress off-target cell death (Robu et al., 2007), at 1.5-fold greater mass amount than the mass of 
experimental or control MO, as indicated in Table 2. The p53 MO sequence is:  
5’-GCGCCATTGCTTTGCAAGAATTG-3’.  
Finally, where the mutant lines were available, for cdipt and tbx24, the MO-induced LOF 
phenotypes were compared, or in the cases of aldoaa and kif22, the effects of shRNAs were examined. 
 
Phenotypic scoring procedures 
Embryos were scored live using brightfield imaging, or after fixation for axon tracts using  
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scanning confocal imaging. Where there was any ambiguity, or a question of whether phenotypic rescue 
had been achieved, another lab member scored the embryos. For most genes, more than one of the authors 
independently assayed MO effects or ability to be rescued by RNA injection. Results were almost always 
concordant. We required ~70% of embryos in a condition to have an aberrant phenotype in at least 2 
independent experiments, and for the phenotype to be rescued by RNA co-injection.  
 
Morphological assays 
 LOF embryos were examined by brightfield and fluorescence microscopy, at 24 hpf, for brain 
morphology, after injection of the brain ventricles with Texas Red dextran (Gutzman and Sive, 2009). 
Embryos were scored for presence of forebrain, midbrain and hindbrain hingepoints, brain ventricle size 
and volume, forebrain truncation and eye morphology. Trunk and tail morphology, and the shape of 
muscle segments were scored by brightfield microscopy or by staining actin filaments with phalloidin 
(described below). Phenotypes existing in greater or equal to 70% of embryos and also meeting 
specificity criteria were included in results unless otherwise stated. 
 
Movement assays 
Movement in LOF embryos was monitored at 24 hpf and 48 hpf. In 24 hpf embryos spontaneous 
contractions were observed. Spontaneous contractions are previously described (Saint-Amant and 
Drapeau, 1998). At 24 hpf the typical movement consists of side-to-side contractions that result in slow 
coils. Embryos were observed for several minutes, as by 24 hpf the contractions are sporadic.  Touch 
response assays were administered at 48 hpf. For this, a loop of thread was used to gently touch the 
embryos on both the head and the tail. The normal response of a tail stimulus involves the embryo briefly 
swimming (about the length of its body) and landing again on the bottom of the dish, whereas a stimulus 
to the head begins with full coiling of the embryo resulting in repositioning (C-start) (Issa et al., 2011; 
Saint-Amant and Drapeau, 1998).  
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Microscopy  
Methods for brightfield microscopy have been described previously (Gutzman and Sive, 2010). 
Confocal imaging was performed on a Zeiss LSM710, after fixation in 2% TCA (acetylated α-tubulin) or 
4% PFA (phalloidin). 
 
In situ hybridization 
In situ hybridization methods are described elsewhere (Wiellette and Sive, 2003). Probes used are 
described in Table S4 and wildtype 24 hpf embryos that were fixed in 4% PFA were used to assay spatial 
expression.  
 
Immunohistochemistry   
Whole-mount immunostaining used mouse anti-acetylated α-tubulin (Sigma, 1:1000). Goat anti-
mouse Alexa Fluor 488 (Molecular Probes, 1:500) was used as a secondary antibody. Staining by 
phalloidin Texas Red was performed using a previously described method (De Rienzo et al., 2011). 
 
RT-PCR and qPCR  
RT-PCR was performed to monitor expression at developmental time points (Fig. S1) and changes 
in splicing that resulted from MO targeting (Table 2). Total embryo RNA was extracted using Trizol 
(Invitrogen) followed by chloroform extraction and isopropanol precipitation and DNAase treatment or 
RNeasy kit (Qiagen). cDNA synthesis was performed with Super Script III Reverse Transcriptase 
(Invitrogen) and oligodT or random hexamers. Primers for RT-PCR and qPCR are shown in Table S2. 
For detecting changes in splicing, primers were designed around targeted exons.  
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RT-PCR was performed using Hot Start Taq Plus (Qiagen) and primers in Table S2. Primers were 
designed to only recognize normal transcript (see Fig. 5 for primer design strategy). Knockdown was 
confirmed by sequencing PCR products and MO effects on expression of predicted protein are included in 
Table 2. qPCR was performed using a ABI Prism 7900 (ABI). Fluorescence detection chemistry utilized 
SYBR green dye master mix (Roche). The relative amount of product was calculated using ΔCT and 
normalized to Ef1α. Values are reported with standard deviation.  
Each assay was performed in at least two independent experiments. Each experiment contained at 
least 90 embryos per condition divided into three separate RNA preparations (biological replicates). Each 
RNA preparation was used for one reverse transcription reaction, which was then used in triplicate for 
each qPCR reaction (technical replicates). 
 
RNA injections 
 RNA was synthesized using the Message Machine kit (Ambien), and injected as described 
previously (Gutzman et al., 2008). 
 
Western blot analysis 
Methods for Western blot analysis have been described previously (Gutzman and Sive, 2010). 
Human anti-KIF22 antibody (Sigma K1390) used at 1:1000 in 3% BSA and human anti-ALDOA 
antibody (Sigma WH0000226M1) used at 1:1000 in 5% milk were detected with anti-mouse HRP 
secondary antibody (Sigma). Human anti-GAPDH antibody (Abcam ab22555) used at 1: 3000 in 5% milk 
TBS-T and human anti-eIF4E antibody (Cell Signaling 9742S) used at 1:500 in 5% BSA TBS-T were 
detected using anti-rabbit HRP secondary antibody (Cell Signaling). Since the Aldoa antibody is not 
specific for the protein product of aldoaa and is expected to cross-react with aldoab, the Aldoa Western 
blot was performed using heads only, as the aldoab gene is only expressed in the tail (not shown). 
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RNAi methods 
Hairpins for aldoaa and kif22 were designed using Invitrogen Block-IT RNAi Designer software. 
A total of four hairpins per gene was designed and analyzed. Hairpin oligonucleotide pairs were purified 
by SDS-PAGE, annealed by heating to 95oC and slow cooling to 10oC. Annealed oligonucelotides were 
subcloned into the miR30 backbone (Dong et al., 2009), of the I-SceI-miR124:GFP-miR30-pA plasmid, 
prepared by Dr. Jennifer Gutzman. This plasmid consists of the CNS-specific promoter miR124 
(Shkumatava et al., 2009) driving a GFP reporter upstream of the miR30 backbone and an SV40 polyA 
addition site, with the expression cassette flanked by I-SceI restriction sites. Transgenesis was effected by 
the meganuclease (I-SceI) method (Thermes et al., 2002), using fresh I-SceI for each transgenic 
preparation.  
aldoaa hairpin 1318 (binding a site in the 3’ UTR):  
sense strand, 5’-
GGCTAGCAGTTACTTCCTTATGTGTGAAACACTGGTGCACATGATGGAGTGTTTCACACATGGAAGTAAC
C- 3’;  
antisense strand, 5’-
TCGTCAATGAAGGAATACACACTTTGTGACCACGTGTACTACCTCACAAAGTGTGTACCTTCATTGGTCG
G- 3’;  
kif22 hairpin 1616 (binding a site in the 9th exon):  
sense strand, 5’-
GGCTAGCAGGCCGTTGTTTTACTCCATTACACTGGTGCACATGATGGAGTGTAATGGAGTAACAACGGCC
C-3';  
antisense strand, 5’-
GGCTGGGCCGTTGTTACTCCATTACACTCCATCATGTGCACCAGTGTAATGGAGTAAAACAACGGCCTGC
T- 3’ 
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TRANSLATIONAL IMPACT 
Clinical issue 
Copy number variants (CNVs) are segments of DNA ranging from 1,000 bp to several megabases, where 
one genomic copy is either duplicated or deleted, changing the number of gene copies in that interval. 
Because CNVs have been associated with many disorders, from cancer to autoimmune disease to 
neuropsychiatric disorders, understanding the mechanisms by which CNVs can be deleterious is very 
important. Carriers of 16p11.2 CNVs present with a wide range of anomalies, including intellectual 
disability disorder (IDD) and autism spectrum disorders (ASD). Therefore, the genes in this CNV are 
likely integral to normal brain function. With 25 genes identified in the central core interval, it is 
hypothesized that dosage changes in one of more of these genes links the CNV to associated pathologies. 
However, the critical genes in 16p11.2 and the majority of other CNVs are unknown.   
 
Results 
This study utilized the zebrafish as a tool to study activity of genes homologous to those in the human 
16p11.2 interval, and identify which genes from this CNV may be most important for association with 
brain disorders. While zebrafish do not possess the behavioral repertoire necessary to recapitulate human 
behaviors, their gene function is conserved with mammals and they are an ideal system for rapid genetic 
manipulations. These attributes make zebrafish an appropriate system with which to study the large 
number of genes in the 16p11.2 CNV. Of twenty-two homologs identified in zebrafish, twenty-one 
displayed embryonic and larval loss of function phenotypes, demonstrating that this set of genes is very 
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important during development. Twenty genes are necessary for proper brain size and shape, with subsets 
also affecting eye development, axon tract organization, movement behaviors, and muscle formation. 
Because changes in dosage for critical genes in the 16p11.2 are anticipated to be detrimental and lead to 
onset of associated disorders, the authors examined whether these phenotypes persisted when the gene 
produced only 50% of its product, equivalent to losing one copy of a gene. The majority of genes 
analyzed did not have a phenotype at 50% reduction; however, two genes were sensitive to dosage. These 
encode the glycolytic enzyme Aldolase A (Aldoa), and the microtubule motor Kinesin family member 22 
(Kif22). These results suggest that the function of genes encoding Aldoa and Kif22 change with copy 
number, and could link the 16p11.2 CNV to pathologies. 
 
Implications and future directions 
These data show that the 16p11.2 CNV comprises a highly active set of genes, particularly for formation 
of the nervous system, but likely also for nervous system function. Most importantly, two genes were 
identified as having functions that were sensitive to dosage, suggesting that these may be critical in 
connecting the CNV to IDD, ASD and other disorders. Future directions include experiments to 
understand the molecular pathways by which each works, and whether each gene works together with 
others in the 16p11.2 region, which human genetic data would predict. Such data will help define targeted 
assays in mammals, and possible therapeutic directions. This study further shows that zebrafish can be 
used to identify genes that are dosage sensitive from other CNVs implicated in other disorders.   
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FIGURE LEGENDS 
Figure 1. Strategy and isolation of zebrafish (Danio rerio) 16p11.2 homologs. (A) Strategy to use 
zebrafish as a tool to analyze 16p11.2 gene activity. (B) Homologous human and zebrafish genes. Each 
homologous pair is connected by a red line. Genes are shown in relative chromosomal positions (Table 
S1). The mapk3, gdpd3, and ypel3 loci are syntenic, whereas kctd13, sez6l2, and asphd1 genes are 
grouped, but order on the human chromosome is different. The cluster tbx24, ppp4cb, and aldoab genes 
have conserved order, but the region includes intervening genes. Single fish icon, single homolog; two 
fish icons, multiple homologs; blue dot, teleost homolog, but no Danio rerio homolog; red box, no teleost 
homologs identified; black bar, synteny; H. s., Homo sapiens; D. r., Danio rerio; Chr., chromosome. 
 
Figure 2. Loss of function (LOF) embryos have abnormal brain and tail morphology. (A) Embryonic 
phenotypes were observed at 24 hpf, after LOF effected by injection of antisense morpholino 
oligonucleotides (MO) (Table S2) at the one to two cell stage (Table S3). Genes assayed (Table S1) are 
indicated above each set of images. “Control” embryos were injected with control MO (Methods). Brain 
ventricles are injected with Texas Red dextran, and brightfield and fluorescence images superimposed. 
Images are representative of phenotypes observed in at least 70% of embryos, over 2-7 independent 
experiments, with 50-350 embryos total assayed per gene (Table S3). (a-w): dorsal views; (a’-w’) lateral 
close-up; (a”-w”) full embryo lateral view. (a-a”) schematics of embryo landmarks. F, forebrain ventricle; 
M, midbrain ventricle; H, hindbrain ventricle.  (b-w) and (b’-w’) anterior to the left, and images are 
shown at equivalent magnification. (B) Phenotypic group where LOF embryos have narrow midbrain and 
hindbrain ventricles. Gene assayed is indicated above each panel. Dorsal views, anterior to the left. F, 
forebrain ventricle; M, midbrain ventricle; H, hindbrain ventricle; MHB, midbrain-hindbrain boundary. 
(C) Phenotypic group where LOF embryos have a straight midbrain. Gene assayed is indicated above 
each panel. Dorsal views, anterior to the left. FB, forebrain; MHB, midbrain-hindbrain boundary; asterisk, 
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
Ac
ce
pt
ed
 m
an
us
cr
ip
t
 39 
midbrain hingepoint; scale bar = 150 µm. Embryo images in (B) and (C) are the dorsal view panels of 
(A).   
 
Figure 3. Phenotypes obtained after LOF of zebrafish 16p11.2 homologs. Embryonic phenotypes 
observed after LOF (Fig. 2) are cataloged and structures or assays are indicated at the top of each column. 
All assays were done in comparison to embryos injected with control MO. Quantification of phenotypes 
is given in Table S3 and rescue conditions are shown in Fig. 4 and Table 3. 
a Genes assayed are indicated in the left column and gene identifiers are included in Table S1. MOs 
targeting these genes are included in Table S2.  
b Morphological analyses addressed head morphology (brain ventricle shape and eye formation), tail 
shape and length, and muscle segment shape (chevron vs. U-shape).  
c Two types of movement were tested: spontaneous movement at 24 hpf, and touch response at 48 hpf. 
The ino80e LOF embryos respond with one flip of the tail or not at all. mapk3 LOF embryos have a jerky 
response and the ypel3 LOF embryos move in small, jerky circles. mvp LOF embryos range from not 
responding to spinning in response to touch. Otherwise, touch response was weak, sluggish, or absent.   
d Initial axon tracts form by 36 hpf and were assayed by immunostaining for acetylated tubulin. Axon 
tracts were not assayed in mvp LOF due to lack of rescue, in prrt2 LOF due to lack of observable 
phenotype at these time points, and in tbx24 LOF due to lack of head expression. 
e Pigmentation was observed at 48 hpf in LOF embryos and images are included in Fig. S3. 
f Persistence of early phenotypic abnormalities was monitored up to 5 dpf. 
1 The mvp MO used for the phenotype reported is indicated with matching superscript and listed first in 
Tables 1 and S2. 
Red boxes: abnormal phenotype in >70% embryos; speckled red boxes: abnormal phenotype in >70% of 
embryos, but the phenotype was mild. ND, not determined.  
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Figure 4. Human orthologs rescue zebrafish LOF embryos. Single cell embryos were injected with 
MO, either alone or together with human or fish mRNA, and imaged at 24 hpf after injecting Texas Red 
dextran into the brain ventricles. The human homolog co-injection with a zebrafish LOF whose phenotype 
is thusly significantly restored to normal, indicates functional equivalence with the zebrafish gene 
(orthology). kctd13 ((L0-L”’) and maz LOF (O0-O”’) were rescued by zebrafish but not human RNA. (B0-
T0) dorsal views and (B”-T”) lateral views of LOF embryos. (B’-T’) dorsal views and (B”’-T”’) lateral 
views of LOF embryos plus rescue mRNA. Human RNAs co-injected for rescue are indicated by upper 
case letters, except for z.kctd13 and z.maz, which refer to RNA from the zebrafish genes.  The rescue 
experiments shown in D, E, and G are from the experiment shown in Fig. 2, in other cases, the images are 
taken from different experiments, with data consistent to that shown in Fig. 2. Images are representative 
of 2-4 independent experiments per gene, with 40-194 embryos total assayed per gene. Rescue of the 
abnormal LOF phenotypes was achieved in ~50% or more of the embryos. Representative images are 
shown here and quantification is included in Table 3. 
 
Figure 5. Axon tracts are abnormal in LOF embryos.  Forebrain and hindbrain axon tracts after LOF. 
Axons were labeled with acetylated α-tubulin antibody, and imaged by scanning confocal microscopy of 
fixed, flatmounted 36 hpf LOF embryos.  (A-M) lateral view, showing forebrain axons. (A’-M’) dorsal 
view, showing hindbrain axons. Genes targeted for LOF by MO injection are indicated above each set of 
panels in lowercase. Over two independent experiments, an average of 8 embryos per gene was imaged 
for effects of LOF and rescue. The percentage of affected embryos was 80% or greater. Hindbrain and 
forebrain tracts were affected in all LOF conditions, except kctd13, which only showed defects in the 
hindbrain and kif22, which only showed defects in the forebrain. The rescues with cognate RNA led to 
rescue in 75-100% of embryos assayed. Human RNAs co-injected for rescue are indicated by upper case 
letters, except for z.kctd13, which refers to RNA from the zebrafish gene. “Control” embryos were 
injected with control MO (Methods). ac, anterior commissures; sot, supra optic tract; poc, post optic 
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commissure; tpoc, tract of the post optic commissure; tpc, tract of the posterior commissure; r2, r4, r6, 
rhombomeres 2, 4, and 6; asterisk, reduced or disorganized ac; arrowhead, reduced or disorganized sot; 
arrow, reduced tpc; open arrowhead, reduced or disorganized tpoc; dotted arrow, reduced poc.   
 
Figure 6. Identification of deletion dosage sensor genes. (A) Strategy for identification of deletion 
dosage sensor genes. MOs designed against splice sites are titrated to find the lowest amount resulting in 
a phenotype, with at least 70% penetrance, and normal RNA remaining at this MO concentration is 
determined. A “deletion dosage sensor” is defined as a gene where a phenotype is observed when ~50% 
of the normal mRNA remains.  (B) Strategy to quantify normal mRNA remaining in LOF embryos. An 
antisense MO is designed to an intron/exon boundary, and typically results in exon exclusion or intron 
inclusion (Table 2). qPCR primers are designed to detect the normally processed mRNA, where one 
primer in each set hybridizes to the normal but not the abnormally processed transcript. For, forward 
primer; Rev, reverse primer; Ex, exon; Intr, Intron. (C) Percentage of normal mRNA remaining in 24 hpf 
LOF embryos. RNA levels were quantified by qPCR, normalized to ef1α and expressed relative to levels 
of experimental RNA in control MO-injected embryos. LOF was performed at two MO concentrations, 
one that did not give a phenotype (“Low MO”) and one that did (“High MO”). Genes assayed are 
indicated below relevant histograms. (D) Quantification of normal aldoaa and kif22 mRNA after LOF in 
18, 24 and 36 hpf embryos, at the same MO concentration used in (C). qPCR was performed and RNA 
levels normalized to ef1a  and expressed relative to levels of experimental RNA in control MO-injected 
embryos.  (E) Western blots of 24 hpf LOF embryos, same MO concentration used in (C), representative 
image of 3 experiments. Protein was extracted from embryos injected with aldoaa or kif22 MOs. After 
LOF, 56% of Aldoa (from head-dissected protein, thus Aldoaa-enriched, see Methods) and 65% of Kif22 
(whole embryo) protein remains when normalized to control proteins (Eif4e and Gapdh, respectively) 
compared to control MO-injected embryos. (F) Muscle segments in 24 hpf LOF embryos. Actin is stained 
with phalloidin, and muscle shape is indicated by white dotted lines. Over two experiments, chevron 
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shape was abnormal in 0% of control MO-injected embryos, 100% aldoaa LOF embryos, and 100% kif22 
LOF embryos (n=10 for each condition). (G) GFP expression in the NeuroD:GFP line. 0% (n=106) 
control embryos (injected with control MO); 94% (n=97) aldoaa LOF embryos; 100% (n=100) kif22 LOF 
embryos affected as observed over four independent experiments. Dotted arrow, retina; arrow, tectum; 
oval, pancreas. (a-a’, c-c’, e-e’) lateral view, anterior to the left, (b-b’, d-d’, f-f’) ventral view. 
 
Figure 7. aldoaa and kif22 function are required in the brain. (A) shRNA expression strategy. 
shRNAs were expressed from a miR30 backbone, under the CNS-specific miR124 promoter. Transient 
transgenesis was induced using I-SceI meganuclease. (B) Relative expression of aldoaa mRNA after 
inhibition by shRNA. Expression was quantified by qPCR in 24 hpf embryos injected with an aldoaa 
hairpin (aldoah) shown relative to embryos injected with a control hairpin (YFPh).  Data was normalized 
to either (a) actin or (b) GFP expression. (c) Touch response in 24 hpf aldoah embryos versus control  
YFPh embryos (81% abnormal, n=26). (C) Phenotype of shRNA-injected embryos. (a-a”) 24 hpf control 
YFPh embryos (16% abnormal, n=51, in 2 independent experiments). (b-b”) 24 hpf aldoah embryos (89% 
abnormal, n=53, in 2 independent experiments). (a, b), lateral view of the head; (a’, b’), dorsal view of the 
head after brain ventricle injection; (a”, b”), lateral view of whole embryo.  (D) Relative expression of 
kif22 mRNA after inhibition by shRNA. kif22 mRNA relative expression was quantified by qPCR in 24 
hpf embryos injected with a kif22 hairpin (kif22h) relative to those injected with the YFPh control hairpin. 
Data was normalized to (a) actin or (b) GFP expression. (E) Phenotype of shRNA-injected embryos. (a-
a”) 24 hpf YFPh embryos (8% abnormal, n=27, in 2 independent experiments). (b-b”) 24 hpf kif22h 
embryos (81% abnormal, n=26, in 2 independent experiments). (a, b), lateral view of the head; (a’, b’), 
dorsal view of the head after brain ventricle injection; (a”, b”), lateral view of whole embryo. 
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Gene 
Namea
Forebrain 
(24 hpf)
Midbrain 
(24 hpf)
Hindbrain 
(24 hpf)
Tail      
(24 hpf)
Muscle 
Segments 
(24 hpf)
Eyes   
(24 hpf)
aldoaa
asphd1
c16orf53
cdipt
coro1a
doc2a
fam57ba
gdpd3
hirip3
ino80e
kctd13
kif22
mapk3
maz
mvp1 ND
ppp4ca
prrt2 ND
sez6l2
taok2a
taok2b
tbx24   ND
ypel3
Morphologyb
Phenotypes
Spontan-
eous 
Movementc 
(24 hpf)
Axon Tractsd 
(36 hpf)
Touch 
Responsec 
(48 hpf)
Pigmentatione 
(48 hpf)
Abnormal    
5 dpf 
Phenotypef
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Gene Namea
Translation 
Start Site 
MOb
Splice Site 
MOc
Change in 
RNA 
Splicingd
Resultant Change 
in Predicted 
Proteine
Phenotype 
Observedf
Phenotype 
Correlates with RNA 
Decreaseg
Rescue by RNA 
Injectionh
Additional 
Knockdown 
Methodi
aldoaa yes yes truncation yes yes, also proteinj yes shRNAk
asphd1 yes yes truncation yes yes yes
c16orf53 yes yes truncation yes yes yes
cdipt yes yes truncation yes yes yes mutantl
coro1a yes yes truncation yes yes yes
yes yes
in frame exon 
deletion
yes ND ND
doc2a yes yes truncation yes yes yes
fam57ba yes yes truncation yes yes yes
gdpd3 yes NA yes yes
hirip3 yes NA yes yes
yes yes truncation no ND NA
ino80e yes NA yes yes
yes yes truncation no ND no
kctd13 yes yes truncation yes yes yes
kif22 yes yes truncation yes yes, also proteinj yes shRNAk
mapk3 yes NA yes yes
yes yes truncation no ND NA
maz yes yes truncation yes yes yes
mvp yes1 yes truncation yes ND no
yes2 NA yes no
yes3 NDm NA yes ND no
ppp4ca yes yes truncation yes yes yes
yes yes
in frame exon 
deletion
no NA NA
prrt2 yes NA no NA
yes yes truncation no NA NA
sez6l2 yes NA yes yes
yes yes truncation no NA NA
taok2a yes yes truncation yes yes yes
taok2b yes yes truncation yes yes yes
tbx24 yes NA yes publishedn mutantl
ypel3 yes yes truncation yes yes yes
Table 1. Summary of tests for antisense morpholino oligonucleotide specificity.  
a  For gene assignments, see Fig. 1 and Table S1.  
b,c MOs were designed as indicated in Methods. See Table S2 for MO sequences.  
d For MOs targeting a splice site, RT-PCR (detailed in Methods) was used to determine whether a change in 
splicing occurred. Primers are included in Table S2. 
e Changes in predicted protein resulting from the RT-PCR-detected change in RNA splicing. Changes are 
described in Table 2.  
f Phenotypes were scored as indicated in Methods (See Fig. 2, 3, and Table S3). 
g MOs were administered in titrations. For splice site MOs where the mass correlated with an increase in 
phenotype severity, qPCR was performed to measure the normal RNA (Fig. 6).  
h RNA was co-injected with MOs to confirm phenotypes were specific effects of the MO (Fig. 3, Table 3).  
i Similar phenotypes were observed for additional knockdown methods (Fig. 7, S2).  
j A decrease in protein was also observed by Western blot analysis of 24 hpf embryos (Fig. 6 and Methods).  
k shRNA was used to target deletion dosage sensors. Similar phenotypes were observed (Fig. 7). 
l Mutant lines were available for cdipt and tbx24 and similar phenotypes were observed (Fig. S2 and Methods). 
m No splicing change was observed in RNA. 
n The rescue for the tbx24 MO was previously published in Nikaido et al., 2002. 
1, 2, 3 mvp MOs 1, 2, and 3, correspond to those included in Tables 2, S2, and S3, although no mvp LOF 
conditions were rescued.  
ND, not determined; NA, not applicable.  
	   Table 1 
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Gene Namea
MO Massb 
(ng/embryo) Results of MO Action on RNA Coding Capacityc
Predicted Proteind 
(Truncated/Normal)      
(Amino Acids)
p53 MO 
Includede
aldoaa 1 exon deletion causing frame shift and early stop codon 202/364 no
asphd1 3.5 intron inclusion containing stop codon 144/354 yes
c16orf53 7.5 intron inclusion containing stop codon 52/273 no
cdipt 7.5 intron inclusion causing frame shift and early stop codon 144/214 no
coro1a 5 intron inclusion causing frame shift and early stop codon 61/455 yes
doc2a 7.5 intron inclusion causing frame shift and early stop codon 184/401 no
fam57ba 1.2 exon deletion causing frame shift and early stop codon 33/202 no
gdpd3 7 translation blocking 0/315 yes
hirip3 6.5 translation blocking 0/510 yes
ino80e 5 translation blocking 0/231 yes
kctd13 7.5 intron inclusion causing frame shift and early stop codon 114/330 no
kif22 5 exon deletion causing frame shift and early stop codon 123/634 yes
mapk3 5 translation blocking 0/392 yes
maz 1.5 intron inclusion causing frame shift and early stop codon 97/493 no
mvp1 5 intron inclusion causing frame shift and early stop codon 45/863 yes
mvp2 6 translation blocking 0/863 yes
mvp3 5 ND ND yes
ppp4ca 3.5 intron inclusion causing frame shift and early stop codon 37/311 yes
prrt2 10 intron inclusion causing frame shift and early stop codon 79/226 no
sez6l2 5 translation blocking 0/892 yes
taok2a 5 intron inclusion causing frame shift and early stop codon 65/1138 no
taok2b 5 intron inclusion containing stop codon 188/1182 no
tbx24 4 translation blocking 0/874 yes
ypel3 2 exon deletion causing frame shift and early stop codon 60/119 yes
Table 2. MO Amounts and Effects on Gene Expression.   
a Genes indicated in Table S1 were targeted in LOF experiments and quantification is included 
in Tables 3 and S3.  
b The MOs (Table S2) were injected at the 1-2 cell stage in titration experiments. The mass of 
MO that was used for phenotype characterization, scoring (Figs. 2, 3 and Table S3) and rescue 
experiments (Figs. 4, 5 and Table 3) is indicated. 
c Splicing changes were monitored by RT-PCR (Methods) using primers indicated in Table S2 
and detected changes were sequenced to identify changes in mRNA, including frame shifts. 
d The predicted changes in protein, based on the sequencing data obtained, are included as the 
number of amino acids in truncated vs. normal protein. Truncated proteins listed may contain 
abnormal amino acids, as amino acids encoded by an intron inclusion or a frame shift are 
predicted (in some cases) before an early stop codon. 
e The p53 MO was used to eliminate off-target effects where indicated.  
1, 2, 3 The mvp MOs are included in the same order as Tables 1, S2, and S3.  
1 Indicates the mvp MO that was used for the LOF collation in Figs. 2A and 3.  
ND, not determined.  	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Gene Namea
Rescue mRNA 
Massb 
(pg/embryo)
Total 
Embryosc
Rescued 
Embryosd
% 
Rescuede
Number of 
Independent 
Experimentsf
aldoaa 200 52 37 71 3
asphd1 100 110 58 53 2
c16orf53 80 48 29 60 2
cdipt 50 107 93 87 3
coro1a 10 74 46 62 2
doc2a 100 90 84 93 2
fam57ba 320 82 69 84 3
gdpd3 20 70 34 49 2
hirip3 100 95 81 85 2
ino80e 200 56 45 80 2
kctd13g 200 80 62 78 2
kif22 15 194 140 72 4
mapk3 5 96 85 89 4
mazg 50 102 80 78 2
ppp4ca 30 116 116 100 3
sez6l2 100 43 24 56 2
taok2a 200 85 49 58 2
taok2b 200 77 51 66 2
ypel3 75 40 33 83 2
Table 3. Rescue Assays with Human or Fish Genes after MO LOF. Representative images of 
embryos from rescue experiments are shown in Fig. 4.  
a Genes indicated in Table S1 were targeted in LOF experiments by MOs included in Table S2, 
using MO masses described in Table 2.  
b Mass of mRNA for rescue was determined based on a titration used for single cell embryo 
injections. In control and LOF conditions a balancing amount of membrane targeted GFP mRNA 
was co-injected to achieve the equivalent load in the rescue condition (Methods). Where more 
than one MO was tested per gene, the rescue of LOF experiment was performed using the first 
MO listed for a gene in Table S2. cDNA constructs included in Table S4 and RNA preparation 
described in Methods.  
c Total embryos scored over 2-4 experiments.  
d Number of embryos whose phenotype was significantly restored to normal.  
e Percentage of rescued embryos relative to total embryos injected.  
f 2-4 independent experiments were performed per rescue condition after the preferred titrated 
dosage was determined. 
g 2-4 kctd13 and maz LOF phenotypes were rescued using zebrafish mRNA using the indicated 
masses. All other rescue mRNA masses refer to human mRNA. 
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Figure S1	  	  
	  
Figure S1. 16p11.2 homologs are expressed during development and in the brain. (A) 
RNA expression analysis by RT-PCR. Total embryo RNA was analyzed for expression of 
16p11.2 homologs at 2.5 hpf (blastula), 6 hpf (early gastrula), 11 hpf (late gastrula), 18 hpf 
(mid-somitogenesis), 24 hpf and 48 hpf. Most genes are expressed maternally, at 2.5 hpf, and 
expression persists zygotically (6 hpf and later). asphd1, doc2a, prrt2 and sez6L2 show 
zygotic expression only, suggesting that these genes act later in development. tbx24 
expression declines sharply by 48 hpf, suggesting a narrow temporal activity window.  
Further, this gene is not expressed in brain. (B) Spatial expression analysis by whole mount in 
situ hybridization. Gene expression was analyzed at 24 hpf (see Methods and Table S4). (a-t) 
dorsal view, (a’-t’) lateral view. All genes except tbx24 were expressed in the brain.	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Figure S2 	  
	  
Figure S2. Similar phenotypes after LOF by MO injection and in genetic mutants. (A, A’) 
cdipt hi559Tg/hi559Tg were scored by genotyping (see Methods for details). (B, B’) cdipt antisense 
morpholino LOF embryo. In both cases, embryos have a narrow forebrain and midbrain 
ventricle. (C-C’) tbx24 te314/te314 were scored by morphology. (D-D’) tbx24 antisense morpholino 
LOF embryo. In both cases, fused muscle segment borders and shorter tails are apparent. (A-D) 
dorsal view, (A’-D’) lateral view.  	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Figure S3 
 
 
 
Figure S3. Pigmentation is abnormal in LOF embryos. Pigment cells were observed after 
LOF, at 48 hpf, by brightfield imaging. Rostral and midline cells were specifically scored as a 
measure of normal melanocyte migration. (A-I) dorsal views. Genes targeted for LOF by MO 
injection are indicated above each set of panels. Red arrowhead, no rostral pigment cells; red 
arrow, no midline pigment cells; scale bar, 150 µM. Average of 35 embryos assayed per gene, 
over 2-4 independent experiments, 70-100% affected compared to control MO-injected embryos.  
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Table S1 
	  
	  	  	  	   	  
Zebrafish Gene Percent Identity with Homolog ind: 
D.rerio Gene Namea Ensembl Identifierb Chromosomal Locationc Human Fugu Medaka Mouse
aldoaa ENSDARG00000011665 Chr. 3: 39.56 84 92 93 85
aldoab ENSDARG00000034470 Chr. 12: 4.75Rev 84 ND ND 82
asphd1 ENSDARG00000075813 Chr. 3: 14.87 52 ND 72 50
c16orf53 ENSDARG00000076966 Chr. 12: 4.31 50 54 60 48
cdipt ENSDARG00000070686 Chr. 3: 21.35 69 70 76 60
coro1a ENSDARG00000054610 Chr. 3: 31.09Rev 69 85 84 69
doc2a ENSDARG00000078736 Chr. 3: 15.15 63 81 48 63
fam57ba ENSDARG00000026875 Chr. 3: 21.15 58 ND 73 58
fam57bb ENSDARG00000074564 Chr. 12: 4.34Rev 60 ND 74 55
gdpd3 ENSDARG00000074466 Chr. 3: 23.47Rev 46 67 66 44
gdpd3 (incomplete)e ENSDARG00000006944 Chr. 12: 4.58Rev 48 61 60 47
hirip3 ENSDARG00000027749 Chr. 3: 14.81Rev 32 ND 37 30
ino80e ENSDARG00000022939 Chr. 16: 12.02 48 70 74 49
kctd13 ENSDARG00000044769 Chr. 3: 14.83Rev 62 80 80 62
kif22 ENSDARG00000077375 Chr. 12: 5.80Rev 52 70 69 51
mapk3 ENSDARG00000070573 Chr. 3: 26.81 81 83 83 81
maz ENSDARG00000087330 Chr. 3: 21.33Rev 45 ND 44 36
mvp ENSDARG00000021242 Chr. 3: 15.33Rev 68 83 46 68
ppp4ca ENSDARG00000070570 Chr. 3: 26.79 93 95 94 93
ppp4cb ENSDARG00000076439 Chr. 12: 4.65Rev 98 98 98 98
prrt2 ENSDARG00000089367 Chr. 12: 5.77Rev 36 15 9 24
sez6l2 ENSDARG00000076052 Chr. 3: 14.86Rev 56 80 78 56
taok2a ENSDARG00000074899 Chr. 3: 21.37Rev 70 89 87 69
taok2b ENSDARG00000079261 Chr. 12:  4.50Rev 62 70 85 62
tbx24 ENSDARG00000011785 Chr.12:   4.59 19 18 19 20
ypel3 ENSDARG00000055510 Chr. 3: 26.84 89 ND 98 89
Table S1. Gene Assignment and Conservation.  
a  D. rerio gene names, which correspond to homologs indicated in Fig. 1. 
b Ensembl identifiers (Release 62, April 2011).   
c Chromosomal location (Release 62, April 2011). Chromosomal orientation of the zebrafish gene 
is on the plus strand unless the location number is followed by “Rev”. 
d Zebrafish percent identity with human, fugu, medaka, and mouse homologs of human 16p11.2 
genes is shown.  
e As the gdpd3 gene on chromosome 12 is incomplete, the gdpd3 gene on chromosome 3 was 
used for all phenotypic assays performed.  
D. rerio, Danio rerio; Chr., chromosome; ND, not determined.  	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Table S2 
 
 
Gene Namea MO Sequence (5' to 3') Splice or Translation Blocking Forward Reverse
aldoaa CCATGCTGAGGAGGAATGCAAGATT Splice Site GACACTGGTTCATGGCATTG GCATCAAAGTGGACAAGGGT
AGATGCATGGCATCGTTCCAATCG# GGGCCTTGTACACAGCAGCCA#
asphd1 GAGAGCTTCCCATGTCTGACCTGAT Splice Site AGCAGCTCAGGCCGTTCCTCAT GAGTGGGAACACAGTCTGGCCCTTT
GCAATCAGGCCAGGATCAAT# ATAGCTGGCCTCCAGAACCT#
c16orf53 GGAGTGTTGTAAAGCTCATACTGTT Splice Site CGCTGGGAGTCGGTGAACGG CTCCTGCGTGTGGTCCTGCG
CGACGGAGGACAACACTGCAGAAG# CTCCTCATCACTGTAAGGGATCATCC#
cdipt TTGTACCTAAGGACGAGGCACGAAT Splice Site GCCAGACTTCAGCAGACACA TTTAATCGGATATGCCCGTATCGTAC
GTGCGCTCAATCAAGGTACAAAATTTGGTGC# ACGGGTACAGCAGTGCCAGGT#
coro1a TGGTTTCTGATGTGGTTTACCTGCA Splice Site GAGGAGCCTTCATTGTCCTG ACGTTCCAGAGGATCACCAC
TGTAGTGTCATGATCTGGGAGA# TCACAGCCTGCACTCATTAG#
ATGAAGTCCTTGTCACTCACCATGA Splice Site ATCTGGGAGATTCCAGAGGG^ ATTATCACAGCCTGCACTCAT^
doc2a CGCAGCTACACAATCACAGGAATGA Splice Site ACTGCGCTGGGGACGCTAGA AATCCCCCTCGCCGGGACTC
GCACCATCATCAGAGCAAAGGGTTTG# TTGGCCTTGCATGCTCCTGGTAGA#
fam57ba ATGCCTGGAAGGAAAATGGAAGAGA Splice Site ATCTGACGCTGCTCAACCTT ATAATCCCCTTTGCCCTGTC
CTTGTAAAGACATCATCGAGGACCAGC# GTACCAGTAGCACAAGAACATGGCA#
gdpd3 GCTCGCCATATTTCCCAAAACAATT Translation Start Site NA NA
TGTTTTCCGCAAATTTCCTC* CAGCGCTTTTCTCATTGTCA*
hirip3 TTATCGCGTCCTTTTCTTTGGCCAT Translation Start Site NA NA
CTTTTCAGTCACTTGTTTACCTGCA Splice Site TGGGAAGAGAGTCGCTCAGT*^ TTCCTCGCTGTCTGAATCCT*^
ino80e CCTCTACTTCTGCTTGCCCGTTCAT Translation Start Site NA NA
AACGGGCAAGCAGAAGTAGA*^ GGAAGAGAGTGGACCAACCA*^
AGATGGTAACGTACTTACATACACC Splice Site
kctd13 CCAGCCTTCAATACAAATGGACACA Splice Site GTACTCCCCTGATGTCTGCC CTCTGCGTTTCTGTAATGTGGT
AGCATCGACTCTGAAGGCTGGGTG# CTCCTCCAGCTCCCTCGTGCT#
kif22 CTTTCCTGAGGTGAAGAACAAGAAT Splice Site GTGTTGCTGTGAACGATGGA GGAGCGCTGGTTGAGTTTAG
CAGGCCGTTGTTACTCCATT* CAAAGTGGTAGATGCGCTGA*
GTTTCTGACCTCCGTCAAGC# TCCAACCAGATTGAAGACCTC#
mapk3 GCTACTGCCCGATTCCGCCATCGTT Translation Start Site NA NA
CCTGAACATGACCACACTGG* GGAGGTAGTTCCTGGCCTTC*^
GTACGATATAGCTGAAACGCGGTTA Splice Site CATCATCGGGATCAATGACA^
maz ACTGGTTTTACTGGGAAAGAGAAGA Splice Site ATGCAGCTTGGAGCAATTTT CCTGCTTCCCAAAAGTATGC
ACCCTCCAATCAGATCTTCTC*# GATTCTTCCTGACCGGATTG*
GTTTTACCGGCGGCATGG#
mvp TGCAGTCTTTCAGATTACCTCTCAT1 Splice Site CCCACCTCACCACTACATCC^ AATGTATCCCGGCAACAAAG
GAGGGACCAGGGACCTACAT* TCTGCAACTGAGGGAATGTG*^
TCCATGTTTCTTCCTACGGGCATTC2 Translation Start Site NA NA
GGTCCCTGCCGGATTTAAAACACAG3 Splice Site
ppp4ca GTGGAGTAAAAGGAGTTACCTTGCT Splice Site GCGACTTCACTGACCTGGAC CTGGCCATGTATGTCACCAC
CAAAGCAAGGGAGATTCTGG*#^ CTGTCAGGGTATCGCACCTT*
GTTTGTTTCCGGGACTTCAC#
CCGACCTAAAGACAATCATCAGAGA Splice Site GCAGAGCCGTATTTTCGATG^
prrt2 ACGCCTGATGGTACTCTGTTTCCAT Translation Start Site NA NA
AGAATTTGAAAGTACCGCTCTCTGC Splice Site GGAGAGGTCATCGTGATGGT*^ GCTCCAGACTGTTCCTCGAC*^
sez6l2 TCACAGCAAAAACTGTGGACACCAT Translation Start Site NA NA
GCACTGAACTGAAGAAACAGTTTGT Splice Site TTTCTAGTCCCCGCCCCCTGG*^ AGGTGCACTCCAGTGGGGAAA*^
taok2a TAATGGTGTGGCTTGCTCACAAAGT Splice Site CCGTGTGTTGATTTGAAACG GCCCTGAAGTGCACCGTGGG
GGAGCAGTGTACTTTGCTCACGAT# GGGGTGTCTGAGCTTCTGCAAGA#
taok2b CCATCCTGAAAACACAGCACAACTC Splice Site AAAGCTGCGGCACCCCAACA GCAGGTGATGCCGAGTGACCA
GTGGGCACACCTTACTGGATGGC# TGCCGAGTGACCACACGTCA#
tbx24 CATTTCCACACCCAGCATGTCTCGG Translation Start Site ACATGTGAGATGGCAGCTCGCG* TGAGTTTGGCCCGGTGGAAGGA*
ypel3 CCTACGTTCACCCTAAAAACACAAA Splice Site AGCAGACCAAGGCCAAAACT TCAGTCCCAGCCATTATCCT
GCAGTCAAGGACGAGCCTAC*
TCAAGGACGAGCCTACCTGT# CAGTGTGGTGTGGCAATTCT#
Primer Sequences (5' to 3')cAntisense Morpholino Oligonucleutideb
Table S2. Primer and MO sequences.  
a Gene names corresponding with zebrafish genes included in Table S1 that were  targeted for loss of 
function (LOF) by antisense morpholino oligonucleotides (MOs).  
b MO sequences and primer sequences are listed 5’-3’. Splice site MOs are designed to either the donor 
or acceptor side of the intron - exon boundary. Where multiple MOs are shown for one gene, the top-
most MO was used for phenotypes reported.  
c The first set of primers listed for each gene was used to monitor changes in splicing after MO injection, 
except for translation-blocking MOs (NA).  
1, 2, 3  mvp MOs are included in this order in Tables 1, 2, and S3. mvp MO1 is included in Figs. 2A and 3. 
* Indicates primers used for the developmental expression timing RT-PCR if different from those used 
to monitor changes in splicing.  
# Represents primers used for qPCR.  
^ Indicates primers used to monitor changes in splicing for second or third MOs (see Table 1), whose 
phenotypes are otherwise not reported (aside from reporting for mvp MOs in Tables 2 and S3). 
NA, not applicable.	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Brain Phenotypesb Tail & Muscle Phenotypesc Movement Phenotypesd
Gene Namea
Total 
Embryos
Affected 
Embryos
Abnormal 
Brain %
Total 
Embryos
Affected 
Embryos
Abnormal 
Tail %
Total 
Embryos
Affected 
Embryos
Abnormal 
Movement %
aldoaa 152 141 93 152 140 92 104 88 85
asphd1 198 193 97 115 115 100 115 0 0
c16orf53 90 66 73 90 66 73 90 0 0
cdipt 117 104 89 117 0 0 117 0 0
coro1a 106 94 89 106 92 87 91 87 96
doc2a 140 83 59 140 0 0 140 0 0
fam57ba 169 162 96 169 162 96 71 65 92
gdpd3 88 65 74 100 83 83 99 89 90
hirip3 102 102 100 150 131 87 150 123 82
ino80e 103 100 97 103 97 94 68 68 100
kctd13 165 149 90 115 107 93 75 65 87
kif22 351 308 88 351 313 89 242 238 98
mapk3 158 154 97 158 156 99 124 123 99
maz 202 170 84 201 149 74 46 44 96
mvp1 167 145 87 167 145 87 67 65 97
mvp2 28 18 64 28 18 64 ND ND ND
mvp3 50 50 100 50 50 100 40 40 100
ppp4ca 101 96 95 101 83 82 97 71 73
prrt2 64 5 8 64 5 8 64 1 2
sez6l2 47 42 89 109 99 91 109 0 0
taok2a 71 62 87 71 0 0 21 10 48
taok2b 74 67 91 78 65 83 78 0 0
tbx24 95 0 0 95 95 100 95 95 100
ypel3 49 47 96 49 38 78 47 42 89
Table S3. Quantification of brain, tail, and movement phenotypes. Data was gathered in 2-7 
experiments for each LOF condition and includes 24 - 48 hpf experimental timepoints. Data is 
summarized in Fig. 3 and representative images are shown in Fig. 2.  
a Genes indicated in Table S1 were targeted in LOF experiments by MOs included in Table S2, 
using MO mass tabulated in Table 2. Where multiple MOs were designed, this table represents 
data obtained using the first MO listed in Table S2, aside from mvp, where three genes are listed. 
b Brain phenotypes, including abnormally shaped ventricle neuroepithelium were observed in 24 
hpf LOF embryos using criteria described in Methods and shown in Figs. 2 and 3. Phenotypes 
observed for forebrain, midbrain, and hindbrain were included as a group in the number of 
abnormally affected embryos that is indicated.  
c Summation of major categories of tail and muscle phenotypes (including tail length, extension, 
and shape and muscle segment chevron abnormalities) were observed in 24 hpf LOF embryos 
using criteria described in Methods and data shown in Figs. 2 and 3. The number of abnormally 
affected embryos is indicated. 
d Movement abnormalities (which may arise from motor neuron or muscular defects) include 
grouping of spontaneous movement and touch response defects, which are assays described in 
Methods. The number of abnormally affected embryos are indicated.  
1, 2, 3 The mvp MOs are included in the same order as Tables 2 and S2.  
1 Indicates the mvp MO that is included in Figs. 2 and 3. 
ND, not determined.  	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Table S4 
 
Gene 
Namea
Human or 
Fish Geneb
GenBank 
Accession No.c Parent Vectord
Cloning into pCS2+e                            
(primers 5' to 3' or restriction enzymes)
in situ sense probe 
preparationf
in situ antisense 
probe preparationf
mMessage rescue 
mRNAg
ALDOA human NM_184043.1 pINCY EcoRI/SalI SP6 Pol, NotI RE
aldoaa zebrafish BC065320 pCMV-SPORT6.1 NAh SP6 Pol, NotI RE T7 Pol, KpnI RE 
ASPHD1 human BC126319 pCR4-TOPO EcoRI/XbaI SP6 Pol, NotI RE
asphd1 zebrafish NA NA GATCGGATCCTCTGATCCTCCATCCCACTC SP6 Pol, NotI RE T7 Pol, HindIII RE
GATCCTCGAGAGGTCCACGCTGAAGATGAC
C16ORF53 human BC003640 pOTB7 AAGAATTCCTGCCCTAGTGGCCTATGTCCC  SP6 Pol, NotI RE
AACTCGAGTCAGTATTTCCGCTGCCGAGGG
c16orf53 zebrafish NA NA AAGAATTCTTAATCACCCCGCGCGGCTC SP6 Pol, XhoI RE T7 Pol, EcoRI RE 
AACTCGAGCCCCTCTGAAAGACTGAGCTGTCC
CDIPT human BC001444.2 pOTB7 EcoRI/BglII (blunt) to StuI site in pcs2+ SP6 Pol, NotI RE
cdipt zebrafish BC066511 pCMV-SPORT6.1 NAh SP6 Pol, NotI RE T7 Pol, SpeI RE
CORO1A human BC110374 pCMV-SPORT6 ATTAGGATCCCAGAATGAGCCGGCAGGTGGT SP6 Pol, NotI RE
GCATCTCGAGGGCTCTACTTGGCCTGGACTG
coro1a zebrafish BC055237.1 pME18SFL3 EcoRI/XbaI SP6 Pol, XbaI RE T7 Pol, EcoRI RE 
DOC2A human BC041769 pBluescriptR AAGAATTCGCCAGGGGTGCTGCATGAGG SP6 Pol, NotI RE
AATCTAGATGTGCCGGGACACTGCTGTC
doc2a zebrafish NA NA GATCGGATCCCCCTGCTTCTCCACTGTCTC SP6 Pol, NotI RE T7 Pol, HindIII RE
GATCCTCGAGACTGTGACCTCCAGCGTCTT
FAM57B human BC007892 pOTB7 EcoRI/XhoI SP6 Pol, NotI RE
fam57b zebrafish BC059567 pBluecript SK(-) NAh T3 Pol, XhoI RE T7 Pol, EcoRI RE na
GDPD3 human BC002714 pOTB7 EcoRI/XhoI (Removes 3'UTR) SP6 Pol, NotI RE
gdpd3 zebrafish BC064306 pExpress-1 NAh SP6 Pol, NotI RE T7 Pol, EcoRV RE
HIRIP3 human NM_003609 pCMV6-AC AAGAATTCGAGCCGTCAATCCCGGGTTG SP6 Pol, NotI RE
AACTCGAGTGGGGGTGGCAGAGCTCAGT
hirip3 zebrafish BC055674 pME18SFL3 XhoI SP6 Pol, NotI RE T7 Pol, HindIII RE
INO80E human BC047712.2 pCMV-SPORT6 ATTAGGATCCGGTCATGAACGGGCCGGCGGACG SP6 Pol, NotI RE
GCATCTCGAGCACGGTCACTCCGGGATGTCGAT
ino80e zebrafish BC065338 pCMV-SPORT6 NAh SP6 Pol, XhoI RE T7 Pol, StuI RE
KCTD13 human BI548684.1 pBluescriptR
kctd13 zebrafish BC122284 pME18SFL3 XhoI SP6 Pol, BglII RE T7 Pol, EcoRI RE SP6 Pol, NotI RE
KIF22 human BC028155 pCMV-SPORT6 EcoRI/XhoI (114 n.t. of 3' UTR remains) SP6 Pol, NotI RE
kif22 zebrafish BC154464 pME18SFL3 XhoI SP6 Pol, XbaI RE T7 Pol, EcoRI RE 
MAPK3 human BC013992 pOTB7 TGTAAAACGACGGCCAGTAA SP6 Pol, NotI RE
GGTGCAGAGATGTCTGTCTGG
mapk3 zebrafish BC097073 pCMV-SPORT6 NAh SP6 Pol, XhoI RE T7 Pol, EcoRV RE
maz zebrafish NA NA ACGTCATGATGGATGCAGCTTGG SP6 Pol, NotI RE T7 Pol, EcoRI RE SP6 Pol, NotI RE
CCTCTCTCCTGTTGGTTAGCTG
MVP human BC015623 pOTB7 EcoRI/XhoI (93 n.t. of 3' UTR remains) SP6 Pol, NotI RE
mvp zebrafish BC063949.1 pExpress-1 NAh SP6 Pol, NotI RE T7 Pol, EcoRI RE 
mvp zebrafish BC063949.2 pExpress-1 EcoRI/NsiI SP6 Pol, NotI RE
PPP4C human BC001416 pOTB7 EcoRI/XhoI (301 n.t. of 3' UTR remains) SP6 Pol, NotI RE
ppp4ca zebrafish BC049430 pME18SFL3 EcoRI/XbaI SP6 Pol, XbaI RE T7 Pol, EcoRI RE 
ppp4cb zebrafish BC155609 pExpress-1 NAh SP6 Pol, NotI RE T7 Pol, EcoRV RE
prrt2 zebrafish BC053594 pCMV-SPORT6 NA NA NA NA
SEZ6L2 human BC000567 pOTB7 AAGAATTCAGAGATCGGGGTGAGTCGCCA SP6 Pol, NotI RE
AAACTAGTTGCAGCTGTAGTCTTGGGGTTCA
sez6l2 zebrafish NA NA GATCGGATCCCATACGCCACAATGACGTTC SP6 Pol, NotI RE T7 Pol, HindIII RE
GATCTCTAGACTCCACTGTAATGGGGCTGT
TAOK2 human BC142663 pCMV-SPORT6 AAGAATTCTACCAGGCCAGGCCCCACTC SP6 Pol, NotI RE
AAACTAGTCAGCTaCCTCCAGGGGGGCAG
taok2a zebrafish pGEM-T Easy AGCGGGCGAGCAGGTACAC T7 Pol, SpeI RE SP6 Pol, SacII RE
ATGGGGGCGCTCTCGGCATAA
taok2b zebrafish pGEM-T Easy CCTTCAAAAGCTGCGGCACCC T7 Pol, SpeI RE SP6 Pol, SacII RE
TGATTCAGTGCTTTGTGCAGCACG
TBX6 human BC026031 pOTB7 
YPEL3 human BC050664 pCMV-SPORT6 EcoRI/XhoI (48 n.t. of 3' UTR remains) SP6 Pol, SacII RE
ypel3 zebrafish BC067578 pCMV-SPORT6 NAh SP6 Pol, XhoI RE T7 Pol, KpnI RE 
Table S4. Human and zebrafish cDNA clones.  
a Genes indicated in Fig. 1 for zebrafish and human. 
b Human genes were used for rescue experiments, except for kctd13 and maz. Zebrafish genes 
were used for in situ probe preparation, and for rescue of kctd13 and maz. 
c Clones were ordered for human genes, and where available, for zebrafish genes. 
d Parent vector of clones. 
e cDNAs were subcloned into pCS2+ for in vitro mRNA transcription. Primers or restriction 
sites used for subcloning are listed and were designed to remove the majority of untranslated 
regions of the cDNA, as these can promote degradation in the fish embryo. Primers were also 
used to amplify zebrafish cDNAs where clones were not available. 
f Linearizing enzyme and polymerase used to generate sense and antisense probes. 
g Linearizing enzyme and polymerase used to generate rescue mRNA. 
h The cDNA used for in situ probes was left in the parent vector if appropriate polymerase and 
restriction binding sites were present. 
Pol, polymerase; RE, restriction enzyme; n.t., nucleotide; UTR, untranslated region; NA, not 
applicable. 	  
